Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

Rhea-AI Summary

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company, is participating in two upcoming healthcare conferences. Gaurav Shah, M.D., CEO, will engage in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 2:20 p.m. ET. The company will also attend the Cowen’s 41st Annual Health Care Conference on March 2, 2021. A live audio webcast of the events will be accessible on the company’s website, with a replay available post-conference.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders announces participation at the following upcoming conferences:

• 10^th Annual SVB Leerink Global Healthcare Conference
  • Gaurav Shah, M.D., Chief Executive Officer of Rocket, is scheduled to participate in a fireside chat on Thursday, February 25, 2021, at 2:20 p.m. Eastern Time.

• Cowen’s 41^st Annual Health Care Conference
  • Tuesday, March 2, 2021

A live audio webcast of the presentation will be available on the Investors section of the company’s website, www.rocketpharma.com. A replay of the presentation will be archived on the Rocket website following the conference.

About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. For more information about Rocket, please visit www.rocketpharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005307/en/

FAQ

When will Rocket Pharmaceuticals participate in the 10th Annual SVB Leerink Global Healthcare Conference?

Rocket Pharmaceuticals will participate in the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 2:20 p.m. Eastern Time.

Who is speaking for Rocket Pharmaceuticals at the upcoming conferences?

Gaurav Shah, M.D., the CEO of Rocket Pharmaceuticals, is scheduled to speak during the conferences.

When is Rocket Pharmaceuticals attending Cowen’s 41st Annual Health Care Conference?

Rocket Pharmaceuticals will attend Cowen’s 41st Annual Health Care Conference on March 2, 2021.

Where can I listen to Rocket Pharmaceuticals' conference presentations?

You can listen to Rocket Pharmaceuticals' conference presentations on the Investors section of their website at www.rocketpharma.com.

What therapies is Rocket Pharmaceuticals developing?

Rocket Pharmaceuticals is developing gene therapies for rare childhood disorders, including Fanconi Anemia, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency, and Infantile Malignant Osteopetrosis.